Autor segons l'article: Rosa-M Valls; Elisabet Llauradó; Sara Fernández-Castillejo; Rosa Solà; Francesc Puiggrós; Lluis Arola; Anna Pedret
Departament: Bioquímica i Biotecnologia Medicina i Cirurgia
Autor/s de la URV: VALLS ZAMORA, ROSA MARIA; LLAURADÓ RIBÉ, ELISABET; FERNÁNDEZ CASTILLEJO, SARA; SOLÀ ALBERICH, ROSA MARIA; PUIGGROS LLAVINÉS, FRANCESC; AROLA FERRER, LUIS MARIA; PEDRET FIGUEROLA, ANNA
Paraules clau: Cardiovascular biomarkers Systolic blood pressur HDL-c Low weight Molecular procyanidin
Resum: Background Oligopinۚ (OP) is a quantified extract from French Maritime Pine bark (FMPB) with low molecular weight procyanidins. The cardioprotective effects of OP need to be tested in human clinical intervention trials with an appropriate design. Purpose The aim of the present study was to assess the effect of subchronic consumption of OP on cardiovascular disease risk factors such as lipid profile, systolic blood pressure (BP) and oxidized-Low Density Lipoprotein (ox-LDL) in stage-1-hypertensive subjects. Methods Between February 14 and May 31, 2014, eligible subjects were recruited from the outpatient clinics of Hospital Universitari Sant Joan (Reus, Spain). A total of 24 participants (mean age ± DS; 57.36 ± 11.25; 17 men) with stage-1-hypertension who were not receiving BP-lowering medication and LDL cholesterol < 4.88 mmol/l were randomized in a double-blind, placebo-controlled, crossover study. The subjects received 2 capsules/day with 75 mg of OP or placebo for 5-weeks. Results At 5-weeks, compared to the placebo, OP raised High Density Lipoprotein-cholesterol (HDL-c) by 14.06% (p = 0.012) and apolipoprotein A-1 by 8.12% (p = 0.038) and reduced the ratio of apolipoprotein B-100/A-1 by 10.26% (p = 0.046). Moreover, at 5-weeks, compared to the baseline, OP reduced the systolic BP by 6.36 mmHg (p = 0.014), and decreased ox-LDL concentrations by 31.72 U/l (p = 0.015). Conclusion At 5-weeks, the consumption of 150 mg/day of OP improve lipid cardiovascular profile and represents one of the scarce ways to increase HDL-c in stage-1-hypertensive subjects.
Grup de recerca: Unitat de Recerca de Lípids i Arteriosclerosi Grup de Recerca en Nutrigenòmica
Àrees temàtiques: Health sciences Ciencias de la salud Ciències de la salut
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: rosamaria.valls@urv.cat
ISSN: 0944-7113
Data d'alta del registre: 2016-09-22
Pàgina final: 1461
Volum de revista: 23
Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
Enllaç font original: https://www.sciencedirect.com/science/article/abs/pii/S0944711316301490
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
DOI de l'article: 10.1016/j.phymed.2016.08.007
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2016
Pàgina inicial: 1451
Tipus de publicació: Article Artículo Article
Repositori URV